S&P 500
5,940.46
-0.4%
-23.14
DJI
42,677.24
-0.3%
-114.83
NASDAQ
$19,142.71
-0.4%
-$72.75
Bitcoin
106,318.00
+1.1%
+1,110.85
AAPL
$206.73
-1.0%
-$2.05
AMZN
$204.08
-1.0%
-$2.08
GOOG
$165.14
-1.6%
-$2.73
META
$636.43
-0.6%
-$4.00
MSFT
$457.90
-0.2%
-$0.97
NVDA
$134.22
-1.0%
-$1.34
TSLA
$343.52
+0.4%
+$1.43
Rezolute (NASDAQ: RZLT)
$3.94
(3.8%)
$0.14
Price as of May 20, 2025, 3:58 p.m. ET
Rezolute Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Rezolute Company Info
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.